Comparative Pharmacology
Head-to-head clinical analysis: FIORINAL W CODEINE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIORINAL W CODEINE versus WESTADONE.
FIORINAL W/CODEINE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Aspirin and caffeine provide analgesic and anti-inflammatory effects via COX inhibition and adenosine receptor antagonism, respectively.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg, codeine 30 mg orally every 4 hours as needed; maximum 6 capsules per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Codeine: 2.5-3.5 hours; Butalbital: 35-45 hours; Aspirin: 15-20 minutes (salicylate: 2-3 hours at low doses, up to 15-30 hours at high doses). Clinical context: butalbital's long half-life leads to accumulation with repeated dosing; salicylate half-life increases significantly in overdose.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal elimination: codeine (90% as metabolites, 5-15% unchanged), butalbital (60-70% unchanged, remainder as metabolites), aspirin (80-100% as salicylate and metabolites, pH-dependent). Fecal: minimal (<5%). Total renal elimination accounts for >95% of dose.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist